NQO2

Summary

NQO2 (N-ribosyldihydronicotinamide:quinone dehydrogenase 2, HGNC:7856) is a protein-coding gene on chromosome 6p25.2, encoding Ribosyldihydronicotinamide dehydrogenase [quinone] (P16083). The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthes….

This gene encodes a member of the thioredoxin family of enzymes. It is a cytosolic and ubiquitously expressed flavoprotein that catalyzes the two-electron reduction of quinone substrates and uses dihydronicotinamide riboside as a reducing coenzyme. Mutations in this gene have been associated with neurodegenerative diseases and several cancers. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 4835 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 48 total
• GTEx eGene: eQTL in 50 tissues, sQTL in 50 (q < 0.05)
• Phenotypes (HPO): 3
• ChEMBL bioactivity: 45 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.07 (unconstrained)
• MANE Select transcript: NM_000904

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7856
Approved symbol	NQO2
Name	N-ribosyldihydronicotinamide:quinone dehydrogenase 2
Location	6p25.2
Locus type	gene with protein product
Status	Approved
Aliases	QR2, DHQV, DIA6
Ensembl gene	ENSG00000124588
Ensembl biotype	protein_coding
OMIM	160998
Entrez	4835

Gene structure

Transcript identifiers

Ensembl transcripts: 109 — 100 protein_coding, 9 nonsense_mediated_decay

MANE Select: ENST00000380455

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 2, TSL 3: 1, TSL 5: 5

ENST00000380455, ENST00000338130, ENST00000380430, ENST00000380441, ENST00000380454, ENST00000380472, ENST00000397717, ENST00000426637, ENST00000606474, ENST00000892207, ENST00000892208, ENST00000892209, ENST00000892210, ENST00000892211, ENST00000892212, ENST00000892213, ENST00000892214, ENST00000892215, ENST00000892216, ENST00000892217, ENST00000892218, ENST00000892219, ENST00000892220, ENST00000892221, ENST00000892222, ENST00000892223, ENST00000892224, ENST00000892225, ENST00000892226, ENST00000892227, ENST00000892228, ENST00000892229, ENST00000892230, ENST00000892231, ENST00000892232, ENST00000892233, ENST00000892234, ENST00000892235, ENST00000892236, ENST00000892237, ENST00000892238, ENST00000892239, ENST00000892240, ENST00000892241, ENST00000929205, ENST00000929206, ENST00000929207, ENST00000929208, ENST00000929209, ENST00000929210, ENST00000929211, ENST00000929212, ENST00000929213, ENST00000929214, ENST00000929215, ENST00000929216, ENST00000929217, ENST00000929218, ENST00000929219, ENST00000929220, ENST00000929221, ENST00000929222, ENST00000929223, ENST00000929224, ENST00000929225, ENST00000929226, ENST00000929227, ENST00000929228, ENST00000929229, ENST00000952437, ENST00000952438, ENST00000952439, ENST00000952440, ENST00000952441, ENST00000952442, ENST00000952443, ENST00000952444, ENST00000952445, ENST00000952446, ENST00000952447, ENST00000952448, ENST00000952449, ENST00000952450, ENST00000952451, ENST00000952452, ENST00000952453, ENST00000952454, ENST00000952455, ENST00000952456, ENST00000952457, ENST00000998161, ENST00000998162, ENST00000998163, ENST00000998164, ENST00000998165, ENST00000998166, ENST00000998167, ENST00001014418, ENST00001088532, ENST00001088533, ENST00001088534, ENST00001088536, ENST00001095041, ENST00001106026, ENST00001118853, ENST00001118854, ENST00001122522, ENST00001122523, ENST00001139934

RefSeq mRNA: 4 — MANE Select: NM_000904 NM_000904, NM_001290221, NM_001290222, NM_001318940

CCDS: CCDS4481, CCDS75388

Canonical transcript exons

ENST00000380455 — 7 exons

Exon	Start	End
ENSE00000680401	3016884	3016985
ENSE00000847812	3012544	3012674
ENSE00001083962	3010025	3010189
ENSE00001398818	3019479	3019755
ENSE00001728408	2999894	3000085
ENSE00001777236	3006468	3006559
ENSE00003785120	3015530	3015643

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 97.69.

FANTOM5 (CAGE): breadth broad, TPM avg 1.6852 / max 48.3036, expressed in 882 samples.

Highest expression (Bgee): adrenal gland, adrenal gland cortex, adrenal cortex, adult mammalian kidney, triceps brachii.

Genetic regulation across tissues (GTEx eQTL / sQTL)

NQO2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 50 tissues and its splicing (sQTL) in 50 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 100 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	eqtl	1.5e-154	-1.06	6:3003736:A:G
Skin Sun Exposed Lower leg	sqtl	4.2e-152	-1.32	6:3003736:A:G
Muscle Skeletal	eqtl	1.8e-146	-0.92	6:3003736:A:G
Skin Sun Exposed Lower leg	eqtl	5.0e-144	-0.92	6:3003736:A:G
Skin Not Sun Exposed Suprapubic	sqtl	9.7e-131	-1.24	6:3003736:A:G
Adipose Subcutaneous	sqtl	1.3e-128	-1.32	6:3003736:A:G
Artery Tibial	eqtl	2.8e-128	-0.88	6:3003736:A:G
Artery Tibial	sqtl	1.8e-124	-1.25	6:3003736:A:G
Muscle Skeletal	sqtl	2.6e-123	-1.05	6:3010915:C:T
Thyroid	sqtl	3.1e-122	-1.15	6:3003736:A:G
Skin Not Sun Exposed Suprapubic	eqtl	6.1e-121	-0.91	6:3003736:A:G
Esophagus Muscularis	eqtl	6.8e-121	-1.07	6:3003736:A:G
Adipose Subcutaneous	eqtl	3.4e-119	-0.81	6:3003736:A:G
Esophagus Mucosa	eqtl	2.9e-118	-0.97	6:3003736:A:G
Whole Blood	sqtl	2.5e-117	-1.01	6:3010915:C:T
Nerve Tibial	eqtl	1.2e-110	-0.84	6:3003736:A:G
Nerve Tibial	sqtl	2.9e-109	-1.10	6:3010915:C:T
Heart Left Ventricle	eqtl	3.2e-104	-1.05	6:3003736:A:G
Heart Atrial Appendage	eqtl	3.4e-104	-1.11	6:3003736:A:G
Esophagus Mucosa	sqtl	3.7e-98	-1.14	6:3013080:C:T

FANTOM5 promoters

6 alternative TSS:

Promoter ID	TPM avg	Samples expressed
65504	15.9179	1792
65505	13.3034	1704
65506	2.4246	1064
65499	1.6852	882
65507	0.9466	550
65508	0.5207	299

Top tissues by expression

showing 100 of 293 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left adrenal gland	UBERON:0001234	97.69	gold quality
left adrenal gland cortex	UBERON:0035825	97.62	gold quality
right adrenal gland	UBERON:0001233	97.46	gold quality
right adrenal gland cortex	UBERON:0035827	97.39	gold quality
adrenal cortex	UBERON:0001235	97.19	gold quality
adult mammalian kidney	UBERON:0000082	97.03	gold quality
triceps brachii	UBERON:0001509	96.47	gold quality
right lobe of liver	UBERON:0001114	96.18	gold quality
adrenal gland	UBERON:0002369	96.17	gold quality
gastrocnemius	UBERON:0001388	95.75	gold quality
apex of heart	UBERON:0002098	95.72	gold quality
nephron tubule	UBERON:0001231	95.59	gold quality
adult organism	UBERON:0007023	95.54	gold quality
right coronary artery	UBERON:0001625	95.40	gold quality
muscle of leg	UBERON:0001383	95.30	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.23	gold quality
right atrium auricular region	UBERON:0006631	94.56	gold quality
heart left ventricle	UBERON:0002084	94.46	gold quality
cardiac ventricle	UBERON:0002082	94.27	gold quality
kidney	UBERON:0002113	94.22	gold quality
left coronary artery	UBERON:0001626	94.19	gold quality
adipose tissue	UBERON:0001013	94.11	gold quality
descending thoracic aorta	UBERON:0002345	94.05	gold quality
connective tissue	UBERON:0002384	93.88	gold quality
blood	UBERON:0000178	93.86	gold quality
adipose tissue of abdominal region	UBERON:0007808	93.86	gold quality
omental fat pad	UBERON:0010414	93.85	gold quality
peritoneum	UBERON:0002358	93.82	gold quality
coronary artery	UBERON:0001621	93.80	gold quality
subcutaneous adipose tissue	UBERON:0002190	93.79	gold quality
granulocyte	CL:0000094	93.77	gold quality
liver	UBERON:0002107	93.76	gold quality
kidney epithelium	UBERON:0004819	93.69	gold quality
cortex of kidney	UBERON:0001225	93.66	gold quality
muscle organ	UBERON:0001630	93.66	gold quality
cardiac atrium	UBERON:0002081	93.55	gold quality
right frontal lobe	UBERON:0002810	93.45	gold quality
heart	UBERON:0000948	93.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.37	gold quality
periodontal ligament	UBERON:0008266	93.36	gold quality
popliteal artery	UBERON:0002250	93.25	gold quality
tibial artery	UBERON:0007610	93.25	gold quality
skin of leg	UBERON:0001511	93.22	gold quality
cerebellar hemisphere	UBERON:0002245	93.10	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.09	gold quality
monocyte	CL:0000576	93.04	gold quality
aorta	UBERON:0000947	93.01	gold quality
cerebellar cortex	UBERON:0002129	93.01	gold quality
thoracic aorta	UBERON:0001515	92.92	gold quality
ascending aorta	UBERON:0001496	92.91	gold quality
stromal cell of endometrium	CL:0002255	92.85	gold quality
skin of abdomen	UBERON:0001416	92.81	gold quality
mucosa of stomach	UBERON:0001199	92.70	gold quality
leukocyte	CL:0000738	92.68	gold quality
mononuclear cell	CL:0000842	92.65	gold quality
minor salivary gland	UBERON:0001830	92.65	gold quality
saliva-secreting gland	UBERON:0001044	92.53	gold quality
metanephros cortex	UBERON:0010533	92.52	gold quality
skin of hip	UBERON:0001554	92.50	gold quality
prefrontal cortex	UBERON:0000451	92.46	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.38	gold quality
heart right ventricle	UBERON:0002080	92.30	gold quality
cingulate cortex	UBERON:0003027	92.27	gold quality
left uterine tube	UBERON:0001303	92.25	gold quality
ectocervix	UBERON:0012249	92.21	gold quality
anterior cingulate cortex	UBERON:0009835	92.15	gold quality
zone of skin	UBERON:0000014	92.11	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.10	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	92.09	gold quality
body of pancreas	UBERON:0001150	92.04	gold quality
body of stomach	UBERON:0001161	92.04	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.02	gold quality
right lung	UBERON:0002167	91.90	gold quality
upper leg skin	UBERON:0004262	91.83	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	91.69	gold quality
trabecular bone tissue	UBERON:0002483	91.66	gold quality
mouth mucosa	UBERON:0003729	91.56	gold quality
cerebellum	UBERON:0002037	91.48	gold quality
endocervix	UBERON:0000458	91.41	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.38	gold quality
lower esophagus	UBERON:0013473	91.37	gold quality
tendon of biceps brachii	UBERON:0008188	91.29	gold quality
right ovary	UBERON:0002118	91.22	gold quality
renal glomerulus	UBERON:0000074	91.03	gold quality
gall bladder	UBERON:0002110	90.94	gold quality
renal medulla	UBERON:0000362	90.86	gold quality
left ovary	UBERON:0002119	90.85	gold quality
metanephric glomerulus	UBERON:0004736	90.79	gold quality
metanephros	UBERON:0000081	90.74	gold quality
biceps brachii	UBERON:0001507	90.72	gold quality
amygdala	UBERON:0001876	90.72	gold quality
esophagus	UBERON:0001043	90.57	gold quality
spleen	UBERON:0002106	90.56	gold quality
bone marrow	UBERON:0002371	90.51	gold quality
skeletal muscle tissue	UBERON:0001134	90.35	gold quality
tibial nerve	UBERON:0001323	90.33	gold quality
parotid gland	UBERON:0001831	90.31	gold quality
esophagus mucosa	UBERON:0002469	90.24	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.18	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.14	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6524	no	189.63
E-GEOD-109979	no	173.69
E-MTAB-8271	no	162.96
E-GEOD-124858	no	107.97
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 78 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Kidney	tissue	177.3	high
Tongue	tissue	135.5
Liver	tissue	103.5	medium
Choroid plexus	tissue	100.8
Postcentral gyrus	tissue	98.3
Bone marrow	tissue	68.0	low
Locus coeruleus	tissue	65.1
Adrenal gland	tissue	63.7	medium
Salivary gland	tissue	58.2	low
Skeletal muscle	tissue	57.2	medium
Adipose tissue	tissue	56.2	low
Spinal cord	tissue	52.8
Hippocampus	tissue	50.4	low
Corpus callosum	tissue	50.2
Skin 1	tissue	47.7	not detected
Superior colliculi	tissue	47.6
Medulla oblongata	tissue	47.5
Nucleus accumbens	tissue	43.9
Pons	tissue	43.1
Thalamus	tissue	42.6
Midbrain	tissue	40.8
Pancreas	tissue	40.2	not detected
Substantia nigra	tissue	39.3
Heart muscle	tissue	38.8	medium
Periaqueductal gray	tissue	34.1
Small intestine	tissue	33.4	medium
Duodenum	tissue	33.1	medium
Parathyroid gland	tissue	31.4	low
Cerebral cortex	tissue	31.3	low
Somatosensory cortex	tissue	31.3
Epididymis	tissue	30.9	low
Ventral forebrain	tissue	30.7
Ovary	tissue	30.4	not detected
Hypothalamus	tissue	30.1
Hippocampal formation	tissue	29.9
Gallbladder	tissue	29.4	low
Retina	tissue	28.7
Occipital cortex	tissue	27.7
Temporal cortex	tissue	27.4
Putamen	tissue	27.2
Seminal vesicle	tissue	27.1	low
Breast	tissue	27.0	medium
Septum	tissue	27.0
Placenta	tissue	26.8	low
Vagina	tissue	26.4	not detected
Motor cortex	tissue	26.3
Prostate	tissue	26.2	low
Insular cortex	tissue	25.8
Lung	tissue	25.6	low
Retrosplenial cortex	tissue	25.6
Amygdala	tissue	25.5
Cervix	tissue	25.4	not detected
Entorhinal cortex	tissue	25.4
Appendix	tissue	25.2	not detected
Esophagus	tissue	25.1	not detected
Retrosplenial and cingulate cortex	tissue	25.1
Prefrontal cortex	tissue	25.0
Thyroid gland	tissue	24.9	medium
Basal ganglia	tissue	24.2	low
Urinary bladder	tissue	23.4	low

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Nucleus raphe magnus (94.4), Nuclei of the trapezoid body (93.6), Precentral gyrus (93.3), Vermis (92.5), Flocculonodular lobe (92.4).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): JUND, NFE2L2, SP1, SP3

miRNA regulators (miRDB)

Targeting NQO2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

15 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-193A-3P	98.59	66.36	769
HSA-MIR-193B-3P	98.59	66.62	748
HSA-MIR-4448	97.04	66.22	752
HSA-MIR-6772-3P	97.04	65.89	784

Functional genomics

gnomAD constraint: pLI 7.75e-06, LOEUF 1.07, missense Z 0.719 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000380455 — one region, missense o/e 0.93.

Literature-anchored findings (GeneRIF, showing 35)

• polymorphisms associated with idiopathic Parkinson’s disease (PMID:11688992)
• A significant difference was found between alcoholic patients and controls in genotype frequency at an insertion/deletion site in the promoter region of the NQO2 gene (p = 0.0014). (PMID:12960511)
• the level of NQO2 mRNA is low in AGR patients compared with the control group. Such a reduction in message suggests that the NQO2 gene may be involved in the development of clozapine-induced AGR. (PMID:14617031)
• NQO2 gene may confer susceptibility to a certain form of schizophrenia. (PMID:14639047)
• the NQO2 gene is differentially expressed by the polymorphic promoters in human cells transfected with NQO2 gene reporter constructs. Alterations in NQO2 activity might be an important factor in susceptibility to Parkinson’s disease. (PMID:15451063)
• We propose that induction of NQO2 may relate to the observed increased expression of p53 that, in turn, contributes to the observed suppression of cell growth in both melanoma cell lines. (PMID:15993843)
• the nicotinamide adenine dinucleotide phosphate reduced-diaphorase interneurons in the human striatum. (PMID:16025450)
• The results combined demonstrated that Nrf2 associates with JunD, binds to ARE at nucleotide -1433, and regulates human NQO2 gene expression and induction in response to antioxidants. (PMID:16545679)
• an apparent association between an NQO2 exon 3 single-nucleotide polymorphism and lower enzymatic activity (PMID:17332305)
• The crystal structure of melatonin and 2-iodomelatonin in complex with QR2 provide a detailed description of the enzyme active site; the design of inhibitors of the enzyme might be instrumental in discriminating the role of MT1, MT2 and QR2/MT3 (PMID:18254726)
• Parkinson’s disease patients were analyzed for NQO2 gene promoter polymorphisms. Three allelic variants were I-29, I-16 and D. The association of the D promoter with Parkinson’s disease may be due to an increase in expression of the NQO2 gene. (PMID:18314446)
• This first structural analysis of hQR2 should enable to better understand the biological role of melatonin on this enzyme . (PMID:18502195)
• We observed a nominal significant association between the rs1143684 NQO2 polymorphism and the trajectory of delayed memory recall over time (p=0.029). No other associations were seen with the decline of other cognitive abilities. (PMID:18538895)
• Quinone reductase 2 is a catechol quinone reductase. quinone reductase 2 could play important roles in the regulation of catecholamine oxidation processes that may be involved in the etiology of Parkinson disease. (PMID:18579530)
• nmr studies of QR2 catalytic reaction were performed; results led to conclusion that melatonin is not cleaved to form N1-acetyl-N2-formyl-5-methoxykynurenine by a catalytically active QR2, indicating melatonin is neither a substrate nor a co-substrate (PMID:18826489)
• NQO2 is a susceptibility gene for breast carcinogenesis. (PMID:19351655)
• Our findings challenge the previous assumption that the NQo2 I-16 allele is stable only when paired with another I-16 allele (PMID:19495956)
• The first European study of the SOD2, SOD3, NQO1, and NQO2 roles in pancreatic cancer etiology did not find significant associations. (PMID:20966810)
• The NQO1 609C>T TT genotype and T allele were significantly associated with increased risk for gastric cancer (GC), whereas NQO2 -3423G>A polymorphism did not show any association with GC. (PMID:21294640)
• Results suggest that NQO2, SOD2 and SOD3 may significantly modify prognosis of breast cancer patients. (PMID:21351093)
• NQO2 is a target gene of the BACH1 transcription factor according to ChIP-seq analysis in HEK 293 cells. (PMID:21555518)
• Selective inhibition of NQO2 over NQO1 can be attributed to the bulky aminoalkylamino substituent at the 5-position, which blocks entrance of the indolequinones into the NQO1 active site. (PMID:21718050)
• results suggest that the increase in hippocampal QR2 might be a cause of AD or might promote the progression of AD by causing an increase in the toxic quinone levels and consequent loss of cognitive function. (PMID:21803122)
• both NQO1 and NQO2 modulate the efficacy of AC therapy and that NQO2 is associated with tamoxifen toxicity. (PMID:21946896)
• results indicate a role of NQO2 in the control of AKT/GSK-3beta/cyclin D1 and highlight the involvement of NQO2 in degradation of cyclin D1, as part of mechanism of chemoprevention by resveratrol (PMID:22266466)
• NQO1 609C>T and NQO2 -3423G>A polymorphisms do not seem to play any significant role in susceptibility or prognosis of EC in north Indian population. (PMID:22770696)
• Diplotypes of NQO1 (exon 4 and 6), C-T (OR = 1.56, Pc = 0.007) and T-T (OR = 0.011, Pc = 3.86) was associated with an increased risk for prostate cancer (PCa). NQO2 and MTHFR did not show any risk with PCa. (PMID:23054000)
• This first structure of a reduced quinone reductase shows that reduction of the FAD cofactor and binding of a specific inhibitor lead to global changes in NQO2 structure and is consistent with a functional role for NQO2 as a flavin redox switch. (PMID:23471972)
• NQO2-L47 is less stable towards proteolytic digestion and thermal denaturation than NQO2-F47. (PMID:24631540)
• In patients with Alzheimer’s disease, QR2 is overexpressed in the insular cotex. (PMID:26609153)
• The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2). (PMID:28346733)
• these data suggest that the overexpression of QR2 in brain cells in the presence of catechol quinones might lead to reactive oxygen species-induced cell death via the rapid conversion of superoxide radicals into hydrogen peroxide and then into highly reactive hydroxyl radicals (PMID:29526807)
• Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity. (PMID:31431515)
• An Axis between the Long Non-Coding RNA HOXA11-AS and NQOs Enhances Metastatic Ability in Oral Squamous Cell Carcinoma. (PMID:36142607)
• Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future. (PMID:38254976)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nqo2	ENSMUSG00000046949
rattus_norvegicus	Nqo2	ENSRNOG00000017820
rattus_norvegicus	AABR07044714.1	ENSRNOG00000053936

Paralogs (1): NQO1 (ENSG00000181019)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:104513) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 9 distinct phenotype terms.

Mouse phenotype (MP)	Records
increased granulocyte number	1
abnormal spatial learning	1
abnormal lymphopoiesis	1
abnormal motor learning	1
thrombocytosis	1
abnormal enzyme/coenzyme activity	1
abnormal spatial working memory	1
increased skin tumor incidence	1
enhanced long-term object recognition memory	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RD31	98.9%	Diamond
Cavia porcellus	Q8CHK7	86.0%	Diamond
Haemophilus influenzae Rd KW20	P44803	58.1%	Diamond
Penicillium crustosum	A0A481WNM5	41.8%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
NQO2-AS1	ncRNA	105374888
LINC01011	ncRNA	401232
SERPINB9-AS1	ncRNA	101927730
SERPINB6	protein-coding	5269
SERPINB9	protein-coding	5272

Protein

Protein identifiers

Ribosyldihydronicotinamide dehydrogenase [quinone] — P16083 (reviewed: P16083)

Alternative names: NRH dehydrogenase [quinone] 2, NRH:quinone oxidoreductase 2, Quinone reductase 2

All UniProt accessions (5): A2A2U4, P16083, Q5TD05, Q5TD07, U3KQG7

UniProt curated annotations — full annotation on UniProt →

Function. The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.

Subunit / interactions. Homodimer.

Subcellular location. Cytoplasm.

Activity regulation. Inhibited by melatonin, resveratrol and 5-hydroxytryptamine.

Cofactor. Binds 1 zinc ion per subunit.

Miscellaneous. Uses dihydronicotinamide riboside (NRH) rather than NAD(P)H as an electron donor.

Similarity. Belongs to the NAD(P)H dehydrogenase (quinone) family.

RefSeq proteins (4): NP_000895, NP_001277150, NP_001277151, NP_001305869 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003680	Flavodoxin_fold	Domain
IPR029039	Flavoprotein-like_sf	Homologous_superfamily
IPR051545	NAD(P)H_dehydrogenase_qn	Family

Pfam: PF02525

Enzyme classification (BRENDA)

• EC 1.10.5.1 — ribosyldihydronicotinamide dehydrogenase (quinone) (BRENDA: 7 organisms, 82 substrates, 281 inhibitors, 35 Km, 9 kcat entries)

Substrate kinetics (BRENDA)

19 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
MENADIONE	0.0016–0.0252	7
N-BENZYL DIHYDRONICOTINAMIDE	0.0113–0.0602	5
DIHYDROBENZYLNICOTINAMIDE	0.02–0.0608	4
2,6-DICHLOROPHENOLINDOPHENOL	0.007–0.019	3
17BETA-17-HYDROXYESTR-1(10)-ENE-3,4-DIONE	0.0008	1
3-(4,5-DIMETHYLTHIAZAOL-2-YL)-2,5-DIPHENYLTETRAZ	0.012	1
5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE	0.061	1
CB 1954	0.26	1
COENZYME Q0	0.0137	1
COENZYME Q1	0.0517	1
COENZYME Q2	0.0387	1
DIHYDRONICOTINAMIDE RIBOSIDE	0.028	1
ESTRADIOL-3,4-QUINONE	—	1
MENADIONE/3-(4,5-DIMETHYLTHIAZAOL-2-YL)-2,5-DIPH	0.0023	1
METHYL RED	0.0047	1

Catalyzed reactions (Rhea)

• 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone + H(+) = beta-nicotinamide D-riboside + a quinol (RHEA:12364)

UniProt features (49 total): helix 13, binding site 11, strand 9, turn 6, sequence variant 5, modified residue 2, chain 1, mutagenesis site 1, sequence conflict 1

Structure

Experimental structures (PDB)

showing 30 of 68 structures by resolution:

PDB	Title	Method	Resolution (Å)
4FGL	Reduced quinone reductase 2 in complex with chloroquine	X-RAY DIFFRACTION	1.2
4FGJ	Oxidized quinone reductase 2 in complex with primaquine	X-RAY DIFFRACTION	1.35
4QOD	The value crystal structure of apo quinone reductase 2 at 1.35A	X-RAY DIFFRACTION	1.35
4QOG	Crystal structure of fad quinone reductase 2 in complex with melatonin at 1.4A	X-RAY DIFFRACTION	1.4
5LBY	Structure of the human quinone reductase 2 (NQO2) in complex with crenolanib	X-RAY DIFFRACTION	1.4
5LBZ	Structure of the human quinone reductase 2 (NQO2) in complex with pacritinib	X-RAY DIFFRACTION	1.4
4FGK	Oxidized quinone reductase 2 in complex with chloroquine	X-RAY DIFFRACTION	1.4
3TEM	Quinone Oxidoreductase (NQ02) bound to the imidazoacridin-6-one 6a1	X-RAY DIFFRACTION	1.45
4QOE	The value ‘crystal structure of fad quinone reductase 2 at 1.45A	X-RAY DIFFRACTION	1.45
4U7H	Oxidized quinone reductase 2 in complex with CK2 inhibitor DMAT	X-RAY DIFFRACTION	1.48
1SG0	Crystal structure analysis of QR2 in complex with resveratrol	X-RAY DIFFRACTION	1.5
1XI2	Quinone Reductase 2 in Complex with Cancer Prodrug CB1954	X-RAY DIFFRACTION	1.5
2QWX	Crystal Structure of Quinone Reductase II	X-RAY DIFFRACTION	1.5
3UXE	Design, Synthesis and Biological Evaluation of Potent Quinoline and Pyrroloquinoline …	X-RAY DIFFRACTION	1.5
4XDG	Crystal Structure of Quinone Reductase II in complex with …	X-RAY DIFFRACTION	1.5
3UXH	Design, Synthesis and Biological Evaluation of Potetent Quinoline and Pyrroloquinoline …	X-RAY DIFFRACTION	1.53
4QOF	Crystal structure of fmn quinone reductase 2 AT 1.55A	X-RAY DIFFRACTION	1.55
4QOI	Crystal structure of FMN quinone reductase 2 in complex with melatonin at 1.55A	X-RAY DIFFRACTION	1.55
3NFR	Casimiroin analog inhibitor of quinone reductase 2	X-RAY DIFFRACTION	1.57
3NHL	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its …	X-RAY DIFFRACTION	1.57
2QX8	Crystal Structure of Quinone Reductase II	X-RAY DIFFRACTION	1.6
3O2N	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its …	X-RAY DIFFRACTION	1.6
4QOH	Crystal structure of fad quinone reductase 2 in complex with resveratrol at 1.6A	X-RAY DIFFRACTION	1.6
2QX4	Crystal Structure of Quinone Reductase II	X-RAY DIFFRACTION	1.65
3NHW	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its …	X-RAY DIFFRACTION	1.65
5LBU	Structure of the human quinone reductase 2 (NQO2) in complex with to CL097	X-RAY DIFFRACTION	1.65
3NHP	X-ray Crystallographic Structure Activity Relationship (SAR) of Casimiroin and its …	X-RAY DIFFRACTION	1.7
3TE7	Quinone Oxidoreductase (NQ02) bound to the imidazoacridin-6-one 5a1	X-RAY DIFFRACTION	1.7
2QX6	Crystal Structure of Quinone Reductase II	X-RAY DIFFRACTION	1.75
3FW1	Quinone Reductase 2	X-RAY DIFFRACTION	1.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P16083-F1	98.17	0.99

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Oxidoreductases, Metabolic proteins, Predicted intracellular proteins, Plasma proteins, Human disease related genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol; nucleoplasm

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (11)

Position	Role
12	FAD
201	FAD
223	Zn(2+)
18–21	FAD
104–107	FAD
127–129	substrate
148–151	FAD
156	FAD
174	Zn(2+)
178	Zn(2+)
194	FAD

Post-translational modifications (2)

Type	Positions
Phosphoserine	80, 197

Mutagenesis-validated functional residues (1)

Position	Phenotype
162	loss of activity toward cb1954, no effect toward menadione.

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-211945	Phase I - Functionalization of compounds	curated
R-HSA-211859	Biological oxidations	—
R-HSA-1430728	Metabolism	—

MSigDB gene sets: 168 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, MODULE_93, REACTOME_BIOLOGICAL_OXIDATIONS, GOBP_KETONE_METABOLIC_PROCESS, chr6p25, CAIRO_HEPATOBLASTOMA_DN, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NAD_P_H, KAAB_FAILED_HEART_VENTRICLE_DN, ACEVEDO_LIVER_CANCER_UP, GCM_BECN1, GRADE_COLON_AND_RECTAL_CANCER_UP, GOBP_QUINONE_METABOLIC_PROCESS, MARSON_BOUND_BY_FOXP3_UNSTIMULATED

GO Biological Process (1): quinone catabolic process (GO:1901662)

GO Molecular Function (12): dihydronicotinamide riboside quinone reductase activity (GO:0001512), NAD(P)H dehydrogenase (quinone) activity (GO:0003955), zinc ion binding (GO:0008270), electron transfer activity (GO:0009055), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on other nitrogenous compounds as donors (GO:0016661), chloride ion binding (GO:0031404), protein homodimerization activity (GO:0042803), FAD binding (GO:0071949), melatonin binding (GO:1904408), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): cytosol (GO:0005829), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Biological oxidations	1
Metabolism	1

GO top-level categories

18 GO namespaces:

Category	Terms
binding	2
cellular anatomical structure	2
ketone catabolic process	1
quinone metabolic process	1
oxidoreductase activity, acting on diphenols and related substances as donors	1
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	1
transition metal ion binding	1
molecular_function	1
catalytic activity	1
oxidoreductase activity	1
anion binding	1
identical protein binding	1
protein dimerization activity	1
flavin adenine dinucleotide binding	1
cation binding	1
cytoplasm	1
extracellular vesicle	1
intracellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 12 of 17 annotations. The rest are phylogenetic / computational / electronic (IEA).

12 experimentally-supported GO terms:

GO term	NS	Evidence
quinone catabolic process	BP	direct assay
cytosol	CC	direct assay
extracellular exosome	CC	high-throughput assay
FAD binding	MF	direct assay
chloride ion binding	MF	direct assay
dihydronicotinamide riboside quinone reductase activity	MF	direct assay
electron transfer activity	MF	direct assay
melatonin binding	MF	direct assay
oxidoreductase activity	MF	direct assay
oxidoreductase activity, acting on other nitrogenous compounds as donors	MF	direct assay
protein homodimerization activity	MF	physical interaction
zinc ion binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 658 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NQO2	CRYZ	Q08257	581
NQO2	COMT	P21964	514
NQO2	ARHGEF5	Q12774	490
NQO2	PALB2	Q86YC2	484
NQO2	GPR50	Q13585	444
NQO2	ASMT	P46597	442
NQO2	CYP19A1	P11511	437
NQO2	AANAT	Q16613	429
NQO2	TCIM	Q9NR00	428
NQO2	TXNDC17	Q9BRA2	423
NQO2	MTNR1A	P48039	409
NQO2	GSR	P00390	407
NQO2	GCLC	P48506	406
NQO2	LSM1	O15116	390
NQO2	ADGRB3	O60242	390

IntAct

Human interaction partners of NQO2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

11 partners by confidence:

Partner	Interaction type	MIscore	Records
GORASP2	physical association	0.740	5
LRRC7	physical association	0.720	6
DDIT4L	physical association	0.560	3
EFHC1	physical association	0.560	3
SPG21	physical association	0.560	3
HSCB	association	0.550	4
DGCR6	physical association	0.370	1
PA	physical association	0.370	1
RHOB	physical association	0.370	1
NSF	association	0.350	1
RELB	physical association	0.000	1

BioGRID (34 interactions; top human partners by supporting records): GORASP2 (Two-hybrid; 2 records), LRRC7 (Two-hybrid; 2 records), CENPF (Co-fractionation), CHUK (Affinity Capture-MS), COPS5 (Affinity Capture-MS), CRAT (Co-fractionation), CTBP2 (Affinity Capture-MS), DDIT4L (Two-hybrid), DGCR6 (Two-hybrid), EFHC1 (Two-hybrid), ELMO2 (Co-fractionation), HNRNPL (Affinity Capture-RNA), IGF2BP3 (Affinity Capture-RNA), IKBKB (Affinity Capture-MS), IL32 (Two-hybrid)

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
★ AKT1-NQO2 complex	2	AKT1, NQO2

Disease & clinical

Genetic variants

Variant evidence for NQO2: 48 ClinVar records (0 pathogenic / likely pathogenic); 1 PharmGKB clinical annotation; 3 GWAS associations.

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	2
Benign	2

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 28 predictions of 808):

Position(s)	Effect	Δscore	Sites
6:3000086	donor_loss	1.0000
6:3016882–3016883	acceptor_loss	1.0000	2
6:3000067	donor_gain	0.9900
6:3000086–3000087	donor_loss	0.9900	4
6:3004595	donor_gain	0.9900
6:3006466–3006467	acceptor_loss	0.9900	6
6:3006557	donor_gain	0.9900
6:3006560–3006561	donor_loss	0.9900	5
6:3010190–3010191	donor_loss	0.9900	6
6:3010194	donor_loss	0.9900

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Papillary Cell Carcinoma (TCGA)	favorable	0.000359
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	favorable	0.000483
Breast Invasive Carcinoma (TCGA)	unfavorable	0.000687
Kidney Chromophobe (TCGA)	unfavorable	0.000941

Disease associations

OMIM: gene MIM:160998 | disease phenotypes:

HPO phenotypes

3 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001442	Typified by somatic mosaicism
HP:0003002	Breast carcinoma

GWAS associations

3 associations:

Study	Trait	p-value
GCST009733_90	Urinary metabolite levels in chronic kidney disease	3e-88
GCST006585_673	Blood protein levels	4e-64
GCST009733_118	Urinary metabolite levels in chronic kidney disease	1e-29

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0005116	urinary metabolite measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3959 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 465,096 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

45 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL3187723	BINIMETINIB	4	7,655
CHEMBL76	CHLOROQUINE	4	59,347
CHEMBL1287853	FEDRATINIB	4	3,770
CHEMBL3301622	GILTERITINIB	4	2,542
CHEMBL941	IMATINIB	4	113,105
CHEMBL1289601	LENVATINIB	4	9,224
CHEMBL45	MELATONIN	4	57,288
CHEMBL255863	NILOTINIB	4	39,362
CHEMBL3353410	OSIMERTINIB	4	9,448
CHEMBL2035187	PACRITINIB	4	3,544
CHEMBL2	PRAZOSIN	4	31,292
CHEMBL506	PRIMAQUINE	4	10,353
CHEMBL535	SUNITINIB	4	80,232
CHEMBL3402762	TEPOTINIB	4	1,359
CHEMBL3989868	TUCATINIB	4	3,355
CHEMBL2105728	CRENOLANIB	3	2,278
CHEMBL48361	DABIGATRAN	3	13,643
CHEMBL522892	DOVITINIB	3	5,162
CHEMBL38380	FASUDIL	3	12,137
CHEMBL603469	LESTAURTINIB	3
CHEMBL1908391	MASITINIB	3
CHEMBL165	RESVERATROL	3
CHEMBL1241855	RIGOSERTIB	3
CHEMBL3426621	RIPASUDIL	3
CHEMBL3334567	SAVOLITINIB	3
CHEMBL43184	AMINACRINE	2
CHEMBL206834	BAFETINIB	2
CHEMBL3545215	BMS-911543	2
CHEMBL338604	C-1311	2
CHEMBL1614713	CC-401	2
CHEMBL1822792	MK-2461	2
CHEMBL1232461	MOLIBRESIB	2
CHEMBL3120215	OSI-027	2
CHEMBL521851	PICTILISIB	2
CHEMBL83527	PTEROSTILBENE	2
CHEMBL2386889	SCH-900776	2
CHEMBL514201	TALMAPIMOD	2
CHEMBL2140408	AMG-900	1
CHEMBL3545360	ASP-3026	1
CHEMBL482967	CYC-116	1
CHEMBL2133806	JNJ-38877605	1
CHEMBL1908397	KW-2449	1
CHEMBL3286797	PF-04418948	1
CHEMBL1236107	SGX-523	1
CHEMBL3544932	TAK-901	1

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB clinical annotations

1 annotations by evidence level (1 strongest → 4):

Variant	Association	Level	Drugs	Phenotypes
rs1143684	Efficacy	3	cyclophosphamide;doxorubicin	Breast Neoplasms

PharmGKB variants

1 variants:

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1143684	NQO2	3	1.00	1	cyclophosphamide;doxorubicin

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

2 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs1143684	cytarabine, idarubicin	Toxicity	Genotype CC is associated with increased risk of gastrointestinal toxicity when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.	PMID:33675324
rs1143684	cyclophosphamide, doxorubicin	Efficacy	Allele C is associated with worse prognosis (overall survival and progression-free survival) in patients who were ER-ve/PR-ve negative when treated with cyclophosphamide and doxorubicin in people with Breast Neoplasms as compared to allele T.	PMID:21946896

Binding affinities (BindingDB)

331 measured of 367 human assays (377 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
2,2,2-Trifluoro-N-[2-(6-methoxy-2-phenyl-3H-inden-1-yl)-ethyl]-acetamide	KI	0.00602 nM
2,2,2-Trifluoro-N-[2-(6-methoxy-indan-1-yl)-ethyl]-acetamide	KI	0.0123 nM
2,2,2-Trifluoro-N-[2-(6-methoxy-indan-1-yl)-ethyl]-acetamide	KI	0.0225 nM
N-[2-(6-Methoxy-3H-inden-1-yl)-ethyl]-propionamide	KI	0.0231 nM
(S) N-[2-(6-Methoxy-indan-1-yl)-ethyl]-butyramide	KI	0.0321 nM
2,2,2-Trifluoro-N-[2-(6-methoxy-3H-inden-1-yl)-ethyl]-acetamide	KI	0.0408 nM
(S) N-[2-(6-Methoxy-indan-1-yl)-ethyl]-propionamide	KI	0.041 nM
2,2,2-Trifluoro-N-[2-(7-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-ethyl]-acetamide	KI	0.0469 nM
N-[2-(6-Methoxy-indan-1-yl)-ethyl]-butyramide	KI	0.0553 nM
N-[2-(6-Methoxy-indan-1-yl)-ethyl]-propionamide	KI	0.0728 nM
(S) N-[2-(6-Methoxy-indan-1-yl)-ethyl]-acetamide	KI	0.0733 nM
N-[2-(2-Iodo-5-methoxy-1-methyl-1H-indol-3-yl)-ethyl]-acetamide	KI	0.08 nM
2,2,2-Trifluoro-N-[2-(6-methoxy-5-methyl-indan-1-yl)-ethyl]-acetamide	KI	0.0984 nM
N-[2-(6-Ethoxy-indan-1-yl)-ethyl]-propionamide	KI	0.1 nM
N-[2-(6-Methoxy-indan-1-yl)-ethyl]-acetamide	KI	0.131 nM
Melatonin,2-Chloro	KI	0.2 nM
(E) N-[2-(6-Methoxy-indan-1-ylidene)-ethyl]-propionamide	KI	0.208 nM
N-[2-(6-Methoxy-indan-1-yl)-ethyl]-isobutyramide	KI	0.25 nM
N-[2-(2-Iodo-5-methoxy-6-nitro-1H-indol-3-yl)-ethyl]-acetamide	KI	0.3 nM
CHEMBL511675	IC50	0.302 nM
N-[2-(6-Propoxy-indan-1-yl)-ethyl]-propionamide	KI	0.425 nM
2,2,2-Trifluoro-N-[3-(6-methoxy-indan-1-yl)-propyl]-acetamide	KI	0.526 nM
N-[2-(5-Methoxy-benzofuran-3-yl)-ethyl]-acetamide	IC50	0.6 nM
N-(2-(7-(methylthio)naphthalen-1-yl)ethyl)acetamide	IC50	0.875 nM
(Z) N-[2-(6-Methoxy-indan-1-ylidene)-ethyl]-propionamide	KI	0.927 nM
Melatonin,2-Iodo	IC50	1 nM
N-[2-(2-Iodo-5-methoxy-1-methyl-6-nitro-1H-indol-3-yl)-ethyl]-acetamide	KI	1.1 nM
Pentanoic acid [2-(6-methoxy-indan-1-yl)-ethyl]-amide	KI	1.3 nM
N-[2-(6-Isopropoxy-indan-1-yl)-ethyl]-propionamide	KI	1.5 nM
2,2,2-Trifluoro-N-[2-(6-methoxy-2-phenyl-indan-1-yl)-ethyl]-acetamide	KI	1.6 nM
2,2,2-Trifluoro-N-[2-(3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)-ethyl]-acetamide	KI	1.7 nM
N-[2-(5-Methoxy-1-methyl-1H-indol-3-yl)-ethyl]-acetamide	KI	2.2 nM
CHEMBL37703	IC50	2.51 nM
CHEMBL6074469	IC50	3 nM
CHEMBL457126	IC50	3.02 nM
N-[2-(5,6-Dimethoxy-indan-1-yl)-ethyl]-acetamide	KI	4.1 nM
CHEMBL1945729	IC50	4.1 nM
CHEMBL6082944	IC50	5 nM
NSC-660841	IC50	6 nM
(R) 2,2,2-Trifluoro-N-[2-(6-methoxy-indan-1-yl)-ethyl]-acetamide	KI	6.4 nM
N-[2-(2-Benzyl-6-methoxy-3H-inden-1-yl)-ethyl]-2,2,2-trifluoro-acetamide	KI	6.8 nM
CHEMBL465378	IC50	7.76 nM
5-(2-Diethylamino-ethylamino)-8-methoxy-1-methyl-2,10b-diaza-aceanthrylen-6-one(2.0MHCl)	IC50	9 nM
CHEMBL4514167	IC50	10 nM
CHEMBL457541	IC50	11 nM
(R) N-[2-(6-Methoxy-indan-1-yl)-ethyl]-acetamide	KI	11 nM
2,2,2-Trifluoro-N-(2-indan-1-yl-ethyl)-acetamide	KI	12 nM
CHEMBL455339	IC50	12 nM
CHEMBL1836819	IC50	14 nM
CHEMBL495399	IC50	14.1 nM

ChEMBL bioactivities

403 potent at pChembl≥5 of 463 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.06	Ki	0.088	nM	CHEMBL300056
10.05	IC50	0.08913	nM	CHEMBL300056
9.89	Ki	0.13	nM	CHEMBL300728
9.89	IC50	0.1288	nM	CHEMBL300728
9.74	Ki	0.18	nM	CHEMBL52559
9.70	IC50	0.1995	nM	CHEMBL52559
9.52	IC50	0.302	nM	CHEMBL511675
9.52	Ki	0.3	nM	CHEMBL300728
9.51	Ki	0.31	nM	CHEMBL53622
9.51	IC50	0.309	nM	CHEMBL53622
9.41	IC50	0.39	nM	CHEMBL1770214
8.96	Ki	1.1	nM	CHEMBL300195
8.92	IC50	1.202	nM	CHEMBL300195
8.57	IC50	2.7	nM	CHEMBL504585
8.55	Ki	2.8	nM	CHEMBL33700
8.55	IC50	2.818	nM	CHEMBL33700
8.52	IC50	3.02	nM	CHEMBL457126
8.52	IC50	3	nM	CHEMBL6074469
8.40	Kd	4	nM	PACRITINIB
8.39	IC50	4.1	nM	CHEMBL1945729
8.31	IC50	4.9	nM	CHEMBL1738752
8.30	IC50	5	nM	CHEMBL6082944
8.22	IC50	6	nM	CHEMBL8602
8.21	Ki	6.1	nM	CHEMBL55084
8.19	Ki	6.5	nM	IODOMELATONIN
8.11	IC50	7.762	nM	CHEMBL465378
8.11	IC50	7.7	nM	CHEMBL6078562
8.11	IC50	7.8	nM	PRAZOSIN
8.05	IC50	9	nM	CHEMBL124254
8.04	Ki	9.09	nM	CHEMBL134447
8.04	IC50	9.12	nM	CHEMBL457992
8.04	IC50	9.1	nM	CHEMBL457992
8.00	IC50	10	nM	CHEMBL4514167
7.96	IC50	10.96	nM	CHEMBL457541
7.96	IC50	10.96	nM	CHEMBL493424
7.92	IC50	12.02	nM	CHEMBL455339
7.89	IC50	13	nM	CHEMBL1967497
7.85	IC50	14.13	nM	CHEMBL457539
7.85	IC50	14.13	nM	CHEMBL495399
7.85	IC50	14	nM	CHEMBL1836819
7.84	IC50	14.5	nM	CHEMBL3770674
7.82	IC50	15.2	nM	CHEMBL3770366
7.82	IC50	15	nM	CHEMBL4435240
7.80	IC50	15.85	nM	CHEMBL446329
7.80	IC50	16	nM	CHEMBL125082
7.77	IC50	17	nM	CHEMBL8150
7.75	IC50	18	nM	CHEMBL1237241
7.75	IC50	18	nM	CHEMBL456727
7.74	IC50	18.2	nM	CHEMBL456727
7.74	IC50	18.2	nM	CHEMBL494566

PubChem BioAssay actives

414 with measured affinity, of 933 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[2-(2-iodo-5-methoxy-1-methyl-4-nitroindol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0001	uM
N-[2-(2-iodo-5-methoxy-1-methylindol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0001	uM
N-[2-(2-iodo-5-methoxy-4-nitro-1H-indol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0002	uM
methyl N-[3-(2-acetamidoethyl)-2-iodo-1H-indol-5-yl]carbamate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0003	uM
N-[2-(5-methoxy-1-methyl-4-nitroindol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0003	uM
methyl N-[8-(2-acetamidoethyl)naphthalen-2-yl]carbamate	594258: Binding affinity to human low affinity melatonin (MT3) site of quinone reductase 2	ic50	0.0004	uM
N-[2-(5-methoxy-4-nitro-1H-indol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0011	uM
methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate	594262: Binding affinity to low affinity melatonin (MT3) site of quinone reductase 2	ic50	0.0027	uM
N-[2-(5-methoxy-1-methylindol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0028	uM
8-methyl-2-(4-methyl-3-piperazin-1-ylsulfonylphenyl)imidazo[1,2-a]pyridine	2203527: Inhibition of QR2 (unknown origin)	ic50	0.0030	uM
ethyl 3-(2-acetamidoethyl)-5-methoxy-1H-indole-2-carboxylate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0030	uM
Pacritinib	1425093: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0040	uM
11-amino-10-chloro-2-methyl-9-(methylamino)-3-oxo-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(11),4,6,8(12),9-pentaene-6-carboxamide	643961: Inhibition of human quinone reductase 2 using NMeH as substrate by MTT assay	ic50	0.0041	uM
N-[2-[7-(methylsulfamoyl)naphthalen-1-yl]ethyl]acetamide	594258: Binding affinity to human low affinity melatonin (MT3) site of quinone reductase 2	ic50	0.0049	uM
N-[2-(5-methoxy-1,6,11-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-2(7),3,5,8,10(15),11,13-heptaen-8-yl)ethyl]furan-2-carboxamide	2203526: Inhibition of human QR2 expressed in Escherichia coli preincubated with BNAH or NRH followed by menadione addition by FLUOstar plate reader assay	ic50	0.0050	uM
10-[2-(diethylamino)ethylamino]-8-hydroxy-4,5-dimethoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,7,9,11,13(16),14-heptaen-6-one	479979: Inhibition of human recombinant NQO2 assessed as reduction of DCPIP by spectrophotometry	ic50	0.0060	uM
N-[2-(2-iodo-5-methoxy-1-methyl-6-nitroindol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0061	uM
N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide	107724: Inhibition of 2-[125I]iodomelatonin binding to Melatonin receptor 3 (MT3) of Syrian hamster brain membrane	ki	0.0065	uM
5-methoxy-3-(5-methoxy-2,3-dihydro-1H-indol-2-yl)-1H-indole	2203497: Displacement of 2-[125I]iodomelatonin from QR2 (unknown origin) extracted from hamster brain membrane incubated for 30 mins relative to control	ic50	0.0077	uM
N-[2-(7-hydroxynaphthalen-1-yl)ethyl]but-3-enamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0078	uM
Prazosin	594262: Binding affinity to low affinity melatonin (MT3) site of quinone reductase 2	ic50	0.0078	uM
10-[2-(diethylamino)ethylamino]-5-methoxy-15-methyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one	479979: Inhibition of human recombinant NQO2 assessed as reduction of DCPIP by spectrophotometry	ic50	0.0090	uM
2,2,2-trifluoro-N-[2-(6-methoxy-3H-inden-1-yl)ethyl]acetamide	107722: Ability to inhibit 2-[125I]iodomelatonin specific binding to melatonin receptor 3 (MT3) of Syrian hamster brain.	ki	0.0091	uM
N-[2-[7-(methylsulfamoyl)naphthalen-1-yl]ethyl]furan-2-carboxamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0091	uM
6-methoxy-2-methyl-N-[(E)-pyridin-3-ylmethylideneamino]quinolin-4-amine	1566052: Inhibition of recombinant human NQO2 expressed in Escherichia coli using DCPIP as substrate by spectrophotometry	ic50	0.0100	uM
N-[2-(7-hydroxynaphthalen-1-yl)ethyl]furan-2-carboxamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0110	uM
methyl N-[3-[2-(but-3-enoylamino)ethyl]-1-benzofuran-5-yl]carbamate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0110	uM
8-(acetamidomethyl)-N-methylnaphthalene-2-carboxamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0120	uM
2-methoxy-6-[(E)-[(6-methoxy-2-methylquinolin-4-yl)hydrazinylidene]methyl]phenol	1566052: Inhibition of recombinant human NQO2 expressed in Escherichia coli using DCPIP as substrate by spectrophotometry	ic50	0.0130	uM
2-[(5-methoxy-8-oxo-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-10-yl)amino]-N,N-dimethylethanamine oxide	621612: Inhibition of human recombinant NQO2 assessed as reduction of DCPIP by spectrophotometry	ic50	0.0140	uM
methyl 3-(2-acetamidoethyl)-1-benzofuran-5-carboxylate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0141	uM
3-[2-(7-methoxynaphthalen-1-yl)ethyl]-1,3-oxazolidin-2-one	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0141	uM
acetic acid;4-[5-(3-nitrophenyl)furan-2-yl]benzenecarboximidamide	1281396: Inhibition of human recombinant NQO2 using DCPIPas substrate and NRH as cofactor measured for 1 min by spectrophotometry in the absence of BSA	ic50	0.0145	uM
6-methoxy-2-methyl-N-[(E)-2-phenylethylideneamino]quinolin-4-amine	1566052: Inhibition of recombinant human NQO2 expressed in Escherichia coli using DCPIP as substrate by spectrophotometry	ic50	0.0150	uM
acetic acid;4-[5-(4-nitrophenyl)furan-2-yl]benzenecarboximidamide	1281396: Inhibition of human recombinant NQO2 using DCPIPas substrate and NRH as cofactor measured for 1 min by spectrophotometry in the absence of BSA	ic50	0.0152	uM
methyl N-[3-(2-acetamidoethyl)-1-benzofuran-5-yl]carbamate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0158	uM
10-[2-(diethylamino)ethylamino]-5-hydroxy-15-methyl-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one	479979: Inhibition of human recombinant NQO2 assessed as reduction of DCPIP by spectrophotometry	ic50	0.0160	uM
10-[2-(diethylamino)ethylamino]-3,6-dimethoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,6,9,11,13(16),14-heptaen-8-one	479979: Inhibition of human recombinant NQO2 assessed as reduction of DCPIP by spectrophotometry	ic50	0.0170	uM
6-methoxy-2-methyl-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]quinolin-4-amine	1566052: Inhibition of recombinant human NQO2 expressed in Escherichia coli using DCPIP as substrate by spectrophotometry	ic50	0.0180	uM
N-[2-(7-methylsulfanylnaphthalen-1-yl)ethyl]acetamide	594258: Binding affinity to human low affinity melatonin (MT3) site of quinone reductase 2	ic50	0.0180	uM
4,5,6,7-tetrabromo-1H-benzimidazole	1801064: Fluorescence Titration Assay from Article 10.1021/bi500959t: “Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.”	kd	0.0181	uM
methyl 3-[2-(cyclopentanecarbonylamino)ethyl]-1-benzofuran-5-carboxylate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0182	uM
N-[2-(7-methylsulfonylnaphthalen-1-yl)ethyl]acetamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0209	uM
methyl N-[3-[2-(2-methylpropanoylamino)ethyl]-1-benzofuran-5-yl]carbamate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0229	uM
methyl N-[8-[(cyclopropanecarbonylamino)methyl]naphthalen-2-yl]carbamate	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0240	uM
acetic acid;4-[5-(4-bromophenyl)furan-2-yl]benzenecarboximidamide	1281396: Inhibition of human recombinant NQO2 using DCPIPas substrate and NRH as cofactor measured for 1 min by spectrophotometry in the absence of BSA	ic50	0.0270	uM
Melatonin	107722: Ability to inhibit 2-[125I]iodomelatonin specific binding to melatonin receptor 3 (MT3) of Syrian hamster brain.	ki	0.0276	uM
N-(2-naphthalen-1-ylethyl)methanesulfonamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0282	uM
N-[2-(7-methoxynaphthalen-1-yl)ethyl]benzamide	396398: Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	ic50	0.0288	uM
10-[2-(diethylamino)ethylamino]-8-hydroxy-3-methoxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,7,9,11,13(16),14-heptaen-6-one	479979: Inhibition of human recombinant NQO2 assessed as reduction of DCPIP by spectrophotometry	ic50	0.0310	uM

CTD chemical–gene interactions

96 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	decreases expression, affects binding, increases oxidation, increases reduction, affects localization (+5 more)	9
Valproic Acid	increases expression, affects expression, decreases methylation, affects cotreatment	8
sodium arsenite	increases expression	5
Cyclosporine	affects cotreatment, increases expression, decreases expression	4
Benzo(a)pyrene	decreases methylation, increases expression, increases methylation	3
Clozapine	decreases reaction, increases reduction, increases activity, increases expression, affects response to substance	3
Quercetin	affects binding, decreases reaction, increases reduction, decreases expression	3
Tetrachlorodibenzodioxin	increases expression	3
bisphenol A	increases expression	2
trichostatin A	affects expression, increases expression	2
sulforaphane	increases expression	2
nicotinamide-beta-riboside	decreases reaction, increases oxidation, increases reduction	2
entinostat	increases expression, affects cotreatment	2
N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide	decreases reaction, increases oxidation, increases reduction, increases activity, decreases activity	2
Panobinostat	affects cotreatment, increases expression	2
Estradiol	affects cotreatment, increases expression	2
Melatonin	affects activity, decreases reaction, increases oxidation, increases reduction	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	increases expression	2
Zinc	affects cotreatment, increases expression, affects expression	2
2,6-Dichloroindophenol	increases oxidation, increases reduction, decreases reaction	2
Aflatoxin B1	affects expression, increases methylation	2
Vitamin K 3	increases oxidation, decreases reaction, increases reduction	2
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
chrysoeriol	decreases reaction, increases oxidation, increases reduction	1
hesperetin	affects binding	1
beta-lapachone	increases expression	1

ChEMBL screening assays

93 unique, capped per target: 93 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1016924	Binding	Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells	A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site. — *Eur J Med Chem*

Cellosaurus cell lines

7 cell lines: 6 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1PD	Abcam K-562 NQO2 KO	Cancer cell line	Female
CVCL_D2KZ	Abcam Raji NQO2 KO	Cancer cell line	Male
CVCL_D8RM	Ubigene HCT 116 NQO2 KO	Cancer cell line	Male
CVCL_E1KG	HyCyte HEK293T KO-hNQO2	Transformed cell line	Female
CVCL_TA99	HAP1 NQO2 (-) 1	Cancer cell line	Male
CVCL_WQ16	Abcam Jurkat NQO2 KO	Cancer cell line	Male
CVCL_XR07	HAP1 NQO2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00190697	Phase 4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	Phase 4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	Phase 4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	Phase 4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	Phase 4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	Phase 4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	Phase 4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	Phase 4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	Phase 4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	Phase 4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	Phase 4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	Phase 4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	Phase 4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	Phase 4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	Phase 4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	Phase 4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	Phase 4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	Phase 4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	Phase 4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	Phase 4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	Phase 4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	Phase 4	UNKNOWN	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	Phase 4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06871787	Phase 4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06887933	Phase 4	NOT_YET_RECRUITING	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT07469202	Phase 4	NOT_YET_RECRUITING	CYTALUX Dose Extension Study
NCT00001806	Phase 3	COMPLETED	Methods in Education for Breast Cancer Genetics
NCT00002477	Phase 3	UNKNOWN	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
NCT00002568	Phase 3	COMPLETED	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002641	Phase 3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002717	Phase 3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002764	Phase 3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002819	Phase 3	TERMINATED	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
NCT00002894	Phase 3	COMPLETED	Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002895	Phase 3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	Phase 3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003214	Phase 3	COMPLETED	Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
NCT00003322	Phase 3	COMPLETED	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003636	Phase 3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003644	Phase 3	COMPLETED	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
NCT00003695	Phase 3	COMPLETED	Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer
NCT00003998	Phase 3	COMPLETED	Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
NCT00004115	Phase 3	UNKNOWN	Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy
NCT00004166	Phase 3	COMPLETED	Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy
NCT00004921	Phase 3	COMPLETED	High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
NCT00004934	Phase 3	COMPLETED	Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00005590	Phase 3	COMPLETED	Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
NCT00006356	Phase 3	TERMINATED	Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
NCT00006453	Phase 3	COMPLETED	Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
NCT00006454	Phase 3	COMPLETED	Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
NCT00011986	Phase 3	COMPLETED	Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00028743	Phase 3	COMPLETED	Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00033605	Phase 3	COMPLETED	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
NCT00043082	Phase 3	COMPLETED	S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00050375	Phase 3	TERMINATED	Clinical Trial for Ovarian Cancer (OvaRex®)
NCT00052468	Phase 3	COMPLETED	Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
NCT00057720	Phase 3	COMPLETED	TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
NCT00098878	Phase 3	COMPLETED	Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00102375	Phase 3	COMPLETED	Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer
NCT00102414	Phase 3	COMPLETED	Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for NQO2 across ~30M SureChEMBL compounds — explore on Sugi Predict.